Financial Analysis: Nutra Pharma (OTCMKTS:NPHC) versus Vanda Pharmaceuticals (NASDAQ:VNDA)

Nutra Pharma (OTCMKTS:NPHC – Get Free Report) and Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, analyst recommendations, institutional ownership and profitability.

Institutional & Insider Ownership

88.1% of Vanda Pharmaceuticals shares are held by institutional investors. 61.5% of Nutra Pharma shares are held by insiders. Comparatively, 8.9% of Vanda Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Nutra Pharma and Vanda Pharmaceuticals”s top-line revenue, earnings per share and valuation.

Nutra Pharma has higher earnings, but lower revenue than Vanda Pharmaceuticals.

Volatility & Risk

Nutra Pharma has a beta of -0.29, indicating that its stock price is 129% less volatile than the S&P 500. Comparatively, Vanda Pharmaceuticals has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for Nutra Pharma and Vanda Pharmaceuticals, as provided by MarketBeat.com.

Vanda Pharmaceuticals has a consensus price target of $14.90, suggesting a potential upside of 104.81%. Given Vanda Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Vanda Pharmaceuticals is more favorable than Nutra Pharma.

Profitability

This table compares Nutra Pharma and Vanda Pharmaceuticals’ net margins, return on equity and return on assets.

Summary

Vanda Pharmaceuticals beats Nutra Pharma on 8 of the 12 factors compared between the two stocks.

About Nutra Pharma

(Get Free Report)

Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and homeopathic and ethical drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases primarily in the United States. The company offers Nyloxin and Nyloxin Extra Strength products, which are used as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps, and neuropathic pain, as well as a topical gel for treating joint pain, and pain associated with arthritis and repetitive stress; Pet Pain-Away, a homeopathic, nonnarcotic, nonaddictive, and overthecounter pain reliever to treat chronic pain in companion animals; Luxury Feet, an over-the-counter pain reliever and antiinflammatory product to treat pain or discomfort due to high heels and stilettos; Nyloxin Military Strength for treating pain to the United States Military and Veteran's Administration; and Equine Pain-Away, an over-the-counter topical pain reliever to relieve pain in horses. It is also involved in developing RPI-78M to treat neurological diseases and autoimmune diseases, including multiple sclerosis, adrenomyeloneuropathy, amyotrophic lateral sclerosis, rheumatoid arthritis, and myasthenia gravis; RPI-MN to treat viral diseases comprising human immunodeficiency virus/AIDS and herpes, as well as for general anti-viral applications; RPI-78 for pain and arthritis; and RPI-70 for pain. The company was incorporated in 2000 and is based in Plantation, Florida.

About Vanda Pharmaceuticals

(Get Free Report)

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson’s disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company’s pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.